ERBB2 and neoplasm: The BsAb was much more cytotoxic to HER2-overexpressing tumor cells in the presence of PBMCs or activated T cells than was trastuzumab either alone or in combination with the parental anti-PD1 antibody, independent of PDL1 expression.